ID   NF1_HUMAN               Reviewed;        2839 AA.
AC   P21359; O00662; Q14284; Q14930; Q14931; Q9UMK3;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   18-JUN-2025, entry version 261.
DE   RecName: Full=Neurofibromin;
DE   AltName: Full=Neurofibromatosis-related protein NF-1;
DE   Contains:
DE     RecName: Full=Neurofibromin truncated;
GN   Name=NF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS I AND II).
RX   PubMed=1457041; DOI=10.1089/dna.1992.11.727;
RA   Bernards A., Haase V.H., Murthy A.E., Menon A., Hannigan G.E.,
RA   Gusella J.F.;
RT   "Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and
RT   absence of expression in a neuroblastoma line.";
RL   DNA Cell Biol. 11:727-734(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I).
RX   PubMed=2134734; DOI=10.1126/science.2134734;
RA   Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M.,
RA   Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L.,
RA   Brownstein B.H., Collins F.S.;
RT   "Type 1 neurofibromatosis gene: identification of a large transcript
RT   disrupted in three NF1 patients.";
RL   Science 249:181-186(1990).
RN   [3]
RP   ERRATUM OF PUBMED:2134734.
RX   PubMed=2125369;
RA   Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M.,
RA   Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L.,
RA   Brownstein B.H., Collins F.S.;
RL   Science 250:1749-1749(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I).
RX   PubMed=1783401; DOI=10.1016/0888-7543(91)90017-9;
RA   Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R.,
RA   Andersen L.B., Mitchell A.L., Gutmann D.H., Boguski M.S., Collins F.S.;
RT   "cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of
RT   the NF1 gene product.";
RL   Genomics 11:931-940(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RC   TISSUE=Placenta;
RX   PubMed=1339276; DOI=10.1016/0006-291x(92)91294-z;
RA   Suzuki H., Takahashi K., Kubota Y., Shibahara S.;
RT   "Molecular cloning of a cDNA coding for neurofibromatosis type 1 protein
RT   isoform lacking the domain related to ras GTPase-activating protein.";
RL   Biochem. Biophys. Res. Commun. 187:984-990(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Kidney;
RX   PubMed=7570581; DOI=10.1620/tjem.175.225;
RA   Suzuki H., Takahashi K., Shibahara S.;
RT   "Evidence for the presence of two amino-terminal isoforms of neurofibromin,
RT   a gene product responsible for neurofibromatosis type 1.";
RL   Tohoku J. Exp. Med. 175:225-233(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-80; LEU-678; HIS-1422
RP   AND LEU-2511.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 335-2839 (ISOFORM I), AND
RP   VARIANT NF1 PRO-1953.
RX   PubMed=2114220; DOI=10.1016/0092-8674(90)90253-b;
RA   Cawthon R.M., Weiss R., Xu G., Viskochil D., Culver M., Stevens J.,
RA   Robertson M., Dunn D., Gesteland R., O'Connell P., White R.;
RT   "A major segment of the neurofibromatosis type 1 gene: cDNA sequence,
RT   genomic structure, and point mutations.";
RL   Cell 62:193-201(1990).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 335-2839 (ISOFORMS I AND 6).
RX   PubMed=2116237; DOI=10.1016/0092-8674(90)90024-9;
RA   Xu G., O'Connell P., Viskochil D., Cawthon R.M., Robertson M., Culver M.,
RA   Dunn D., Stevens J., Gesteland R., White R., Weiss R.;
RT   "The neurofibromatosis type 1 gene encodes a protein related to GAP.";
RL   Cell 62:599-608(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 707-782.
RX   PubMed=9002664; DOI=10.1093/hmg/6.1.9;
RA   Regnier V., Meddeb M., Lecointre G., Richard F., Duverger A., Nguyen V.C.,
RA   Dutrillaux B., Bernheim A., Danglot G.;
RT   "Emergence and scattering of multiple neurofibromatosis (NF1)-related
RT   sequences during hominoid evolution suggest a process of pericentromeric
RT   interchromosomal transposition.";
RL   Hum. Mol. Genet. 6:9-16(1997).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 751-1611 (ISOFORMS I AND II).
RX   PubMed=7774960; DOI=10.1016/0888-7543(95)80104-t;
RA   Li Y., O'Connell P., Breidenbach H.H., Cawthon R.M., Stevens J., Xu G.,
RA   Neil S., Robertson M., White R., Viskochil D.;
RT   "Genomic organization of the neurofibromatosis 1 gene (NF1).";
RL   Genomics 25:9-18(1995).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1090-1598 (ISOFORM 4).
RX   PubMed=2121370; DOI=10.1016/0092-8674(90)90150-d;
RA   Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J.,
RA   Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., Innis M.,
RA   McCormick F.;
RT   "The GAP-related domain of the neurofibromatosis type 1 gene product
RT   interacts with ras p21.";
RL   Cell 63:843-849(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1168-1566 (ISOFORMS I AND II).
RX   PubMed=1923522;
RA   Nishi T., Lee P.S., Oka K., Levin V.A., Tanase S., Morino Y., Saya H.;
RT   "Differential expression of two types of the neurofibromatosis type 1 (NF1)
RT   gene transcripts related to neuronal differentiation.";
RL   Oncogene 6:1555-1559(1991).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8417346; DOI=10.1128/mcb.13.1.487-495.1993;
RA   Andersen L.B., Ballester R., Marchuk D.A., Chang E., Gutmann D.H.,
RA   Saulino A.M., Camonis J., Wigler M., Collins F.S.;
RT   "A conserved alternative splice in the von Recklinghausen neurofibromatosis
RT   (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-
RT   activating protein activity.";
RL   Mol. Cell. Biol. 13:487-495(1993).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II).
RX   PubMed=1662505; DOI=10.1016/0006-291x(91)92029-j;
RA   Suzuki Y., Suzuki H., Kayama T., Yoshimoto T., Shibahara S.;
RT   "Brain tumors predominantly express the neurofibromatosis type 1 gene
RT   transcripts containing the 63 base insert in the region coding for GTPase
RT   activating protein-related domain.";
RL   Biochem. Biophys. Res. Commun. 181:955-961(1991).
RN   [18]
RP   FUNCTION.
RX   PubMed=2121371; DOI=10.1016/0092-8674(90)90151-4;
RA   Ballester R., Marchuk D.A., Boguski M.S., Saulino A.M., Letcher R.,
RA   Wigler M., Collins F.S.;
RT   "The NF1 locus encodes a protein functionally related to mammalian GAP and
RT   yeast IRA proteins.";
RL   Cell 63:851-859(1990).
RN   [19]
RP   RNA EDITING.
RX   PubMed=8602361; DOI=10.1093/nar/24.3.478;
RA   Skuse G.R., Cappione A.J., Sowden M., Metheny L.J., Smith H.C.;
RT   "The neurofibromatosis type I messenger RNA undergoes base-modification RNA
RT   editing.";
RL   Nucleic Acids Res. 24:478-485(1996).
RN   [20]
RP   RNA EDITING.
RX   PubMed=11727199; DOI=10.1086/337952;
RA   Mukhopadhyay D., Anant S., Lee R.M., Kennedy S., Viskochil D.,
RA   Davidson N.O.;
RT   "C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express
RT   both the type II transcript and apobec-1, the catalytic subunit of the
RT   apolipoprotein B mRNA-editing enzyme.";
RL   Am. J. Hum. Genet. 70:38-50(2002).
RN   [21]
RP   REVIEW ON VARIANTS.
RX   PubMed=7981724; DOI=10.1002/humu.1380040202;
RA   Upadhyaya M., Shaw D.J., Harper P.S.;
RT   "Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and
RT   polymorphisms in the NF1 gene.";
RL   Hum. Mutat. 4:83-101(1994).
RN   [22]
RP   REVIEW ON VARIANTS.
RX   PubMed=8825042; DOI=10.1136/jmg.33.1.2;
RA   Shen M.H., Harper P.S., Upadhyaya M.;
RT   "Molecular genetics of neurofibromatosis type 1 (NF1).";
RL   J. Med. Genet. 33:2-17(1996).
RN   [23]
RP   SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=14988005; DOI=10.1016/s0014-5793(04)00078-x;
RA   Vandenbroucke I., Van Oostveldt P., Coene E., De Paepe A., Messiaen L.;
RT   "Neurofibromin is actively transported to the nucleus.";
RL   FEBS Lett. 560:98-102(2004).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-2188; SER-2515;
RP   SER-2521 AND SER-2543, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876 AND SER-2515,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864 AND SER-2817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   INTERACTION WITH HTR6.
RX   PubMed=23027611; DOI=10.1002/emmm.201201410;
RA   Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J.,
RA   Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D.,
RA   Fone K.C., Bockaert J., Millan M.J., Marin P.;
RT   "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed
RT   cognition in schizophrenia.";
RL   EMBO Mol. Med. 4:1043-1056(2012).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876; SER-2188;
RP   SER-2515; SER-2521; SER-2523; SER-2543; THR-2565; SER-2597 AND SER-2802,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   INTERACTION WITH SPRED2, AND SUBCELLULAR LOCATION.
RX   PubMed=34626534; DOI=10.1016/j.ajhg.2021.09.007;
RA   Motta M., Fasano G., Gredy S., Brinkmann J., Bonnard A.A.,
RA   Simsek-Kiper P.O., Gulec E.Y., Essaddam L., Utine G.E.,
RA   Guarnetti Prandi I., Venditti M., Pantaleoni F., Radio F.C., Ciolfi A.,
RA   Petrini S., Consoli F., Vignal C., Hepbasli D., Ullrich M., de Boer E.,
RA   Vissers L.E.L.M., Gritli S., Rossi C., De Luca A., Ben Becher S.,
RA   Gelb B.D., Dallapiccola B., Lauri A., Chillemi G., Schuh K., Cave H.,
RA   Zenker M., Tartaglia M.;
RT   "SPRED2 loss-of-function causes a recessive Noonan syndrome-like
RT   phenotype.";
RL   Am. J. Hum. Genet. 108:2112-2129(2021).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1198-1551.
RX   PubMed=9687500; DOI=10.1093/emboj/17.15.4313;
RA   Scheffzek K., Ahmadian M.R., Wiesmuller L., Kabsch W., Stege P.,
RA   Schmitz F., Wittinghofer A.;
RT   "Structural analysis of the GAP-related domain from neurofibromin and its
RT   implications.";
RL   EMBO J. 17:4313-4327(1998).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1581-1837, LIPID-BINDING, DOMAIN,
RP   AND MUTAGENESIS OF LYS-1691; ARG-1695; ARG-1769 AND LYS-1771.
RX   PubMed=16397625; DOI=10.1038/sj.embor.7400602;
RA   D'Angelo I., Welti S., Bonneau F., Scheffzek K.;
RT   "A novel bipartite phospholipid-binding module in the neurofibromatosis
RT   type 1 protein.";
RL   EMBO Rep. 7:174-179(2006).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1566-1837 IN COMPLEX WITH
RP   PHOSPHOLIPID, LIPID-BINDING, AND DOMAIN.
RX   PubMed=17187824; DOI=10.1016/j.jmb.2006.11.055;
RA   Welti S., Fraterman S., D'Angelo I., Wilm M., Scheffzek K.;
RT   "The sec14 homology module of neurofibromin binds cellular
RT   glycerophospholipids: mass spectrometry and structure of a lipid complex.";
RL   J. Mol. Biol. 366:551-562(2007).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 1581-1837 OF VARIANT NF1 VAL-1605
RP   AND MUTANT LYS-1771 DEL IN COMPLEX WITH LIPID, CHARACTERIZATION OF VARIANT
RP   NF1 VAL-1605, MUTAGENESIS OF LYS-1771, LIPID-BINDING, AND DOMAIN.
RX   PubMed=21089070; DOI=10.1002/humu.21405;
RA   Welti S., Kuhn S., D'Angelo I., Brugger B., Kaufmann D., Scheffzek K.;
RT   "Structural and biochemical consequences of NF1 associated nontruncating
RT   mutations in the Sec14-PH module of neurofibromin.";
RL   Hum. Mutat. 32:191-197(2011).
RN   [41]
RP   VARIANT GLU-1444.
RX   PubMed=1568247; DOI=10.1016/0092-8674(92)90408-5;
RA   Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D., Ward K.,
RA   Friedman E., Samowitz W., Robertson M., Bradley P., McCormick F., White R.,
RA   Cawthon R.M.;
RT   "Somatic mutations in the neurofibromatosis 1 gene in human tumors.";
RL   Cell 69:275-281(1992).
RN   [42]
RP   VARIANTS NF1 MET-2164 AND ASN-2192.
RX   PubMed=1302608; DOI=10.1093/hmg/1.9.735;
RA   Upadhyaya M., Shen M.H., Cherryson A., Farnham J., Maynard J., Huson S.M.,
RA   Harper P.S.;
RT   "Analysis of mutations at the neurofibromatosis 1 (NF1) locus.";
RL   Hum. Mol. Genet. 1:735-740(1992).
RN   [43]
RP   VARIANT GLY-HIS-GLU-GLN-GLN-LYS-LEU-PRO-ALA-ALA-THR-LEU-ALA-LEU-1733 INS.
RX   PubMed=8317503;
RA   Tassabehji M., Strachan T., Sharland M., Colley A., Donnai D., Harris R.,
RA   Thakker N.;
RT   "Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a
RT   family with features of Watson syndrome and Noonan syndrome.";
RL   Am. J. Hum. Genet. 53:90-95(1993).
RN   [44]
RP   VARIANT MET-991 DEL.
RX   PubMed=7904209; DOI=10.1093/hmg/2.11.1861;
RA   Shen M.H., Harper P.S., Upadhyaya M.;
RT   "Neurofibromatosis type 1 (NF1): the search for mutations by PCR-
RT   heteroduplex analysis on Hydrolink gels.";
RL   Hum. Mol. Genet. 2:1861-1864(1993).
RN   [45]
RP   VARIANTS NF1 ASP-1166 AND ARG-1440.
RX   PubMed=7981679; DOI=10.1093/hmg/3.7.1109;
RA   Purandare S.M., Lanyon W.G., Connor J.M.;
RT   "Characterisation of inherited and sporadic mutations in neurofibromatosis
RT   type-1.";
RL   Hum. Mol. Genet. 3:1109-1115(1994).
RN   [46]
RP   VARIANT NF1 2387-ASN-PHE-2388 DEL.
RX   PubMed=8081387; DOI=10.1002/humu.1380030404;
RA   Abernathy C.R., Colman S.D., Kousseff B.G., Wallace M.R.;
RT   "Two NF1 mutations: frameshift in the GAP-related domain, and loss of two
RT   codons toward the 3' end of the gene.";
RL   Hum. Mutat. 3:347-352(1994).
RN   [47]
RP   VARIANT NF1 ALA-2631.
RX   PubMed=8544190; DOI=10.1136/jmg.32.9.706;
RA   Upadhyaya M., Maynard J., Osborn M.J., Huson S.M., Ponder M.,
RA   Ponder B.A.J., Harper P.S.;
RT   "Characterisation of germline mutations in the neurofibromatosis type 1
RT   (NF1) gene.";
RL   J. Med. Genet. 32:706-710(1995).
RN   [48]
RP   VARIANT NF1 ARG-629.
RX   PubMed=8834249; DOI=10.1007/bf02267073;
RA   Gasparini P., D'Agruma L., de Cillis G.P., Balestrazzi P., Mingarelli R.,
RA   Zelante L.;
RT   "Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP:
RT   identification of three novel mutations and of two new polymorphisms.";
RL   Hum. Genet. 97:492-495(1996).
RN   [49]
RP   VARIANT NF1 ARG-1035.
RX   PubMed=8807336;
RX   DOI=10.1002/(sici)1098-1004(1996)8:1<51::aid-humu7>3.0.co;2-s;
RA   Wu R., Legius E., Robberecht W., Dumoulin M., Cassiman J.-J., Fryns J.-P.;
RT   "Neurofibromatosis type I gene mutation in a patient with features of
RT   LEOPARD syndrome.";
RL   Hum. Mutat. 8:51-56(1996).
RN   [50]
RP   VARIANTS NF1 SER-1412; GLN-1440; GLU-1444 AND GLY-1489.
RX   PubMed=9003501; DOI=10.1007/s004390050317;
RA   Upadhyaya M., Osborn M.J., Maynard J., Kim M.R., Tamanoi F., Cooper D.N.;
RT   "Mutational and functional analysis of the neurofibromatosis type 1 (NF1)
RT   gene.";
RL   Hum. Genet. 99:88-92(1997).
RN   [51]
RP   VARIANTS NF1 ARG-844 AND PRO-898.
RX   PubMed=9150739; DOI=10.1007/s004390050427;
RA   Maynard J., Krawczak M., Upadhyaya M.;
RT   "Characterization and significance of nine novel mutations in exon 16 of
RT   the neurofibromatosis type 1 (NF1) gene.";
RL   Hum. Genet. 99:674-676(1997).
RN   [52]
RP   VARIANT NF1 ARG-1952.
RX   PubMed=9101300;
RX   DOI=10.1002/(sici)1098-1004(1997)9:4<366::aid-humu12>3.0.co;2-0;
RA   Hudson J., Wu C.L., Tassabehji M., Summers E.M., Simon S., Super M.,
RA   Donnai D., Thakker N.;
RT   "Novel and recurrent mutations in the neurofibromatosis type 1 (NF1)
RT   gene.";
RL   Hum. Mutat. 9:366-367(1997).
RN   [53]
RP   VARIANTS NF1 GLY-338 AND TRP-1611.
RX   PubMed=9298829;
RX   DOI=10.1002/(sici)1098-1004(1997)10:3<248::aid-humu14>3.0.co;2-#;
RA   Upadhyaya M., Maynard J., Osborn M.J., Harper P.S.;
RT   "Six novel mutations in the neurofibromatosis type 1 (NF1) gene.";
RL   Hum. Mutat. 10:248-250(1997).
RN   [54]
RP   VARIANT NF1 PRO-1276.
RX   PubMed=9668168; DOI=10.1093/hmg/7.8.1261;
RA   Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S.,
RA   Gewies A., Schmitz F., Kaufmann D., Peters H., Wittinghofer A.,
RA   Nuernberg P.;
RT   "Selective disactivation of neurofibromin GAP activity in neurofibromatosis
RT   type 1 (NF1).";
RL   Hum. Mol. Genet. 7:1261-1268(1998).
RN   [55]
RP   VARIANTS NF1 HIS-765 AND GLY-1204.
RX   PubMed=10336779;
RX   DOI=10.1002/(sici)1098-1004(1998)11:5<411::aid-humu11>3.0.co;2-2;
RA   Krkljus S., Abernathy C.R., Johnson J.S., Williams C.A., Driscoll D.J.,
RA   Zori R., Stalker H.J., Rasmussen S.A., Collins F.S., Kousseff B.G.,
RA   Baumbach L., Wallace M.R.;
RT   "Analysis of CpG C-to-T mutations in neurofibromatosis type 1.";
RL   Hum. Mutat. 11:411-411(1998).
RN   [56]
RP   VARIANT NF1 PRO-508.
RX   PubMed=11258625; DOI=10.1097/00125817-199909000-00002;
RA   Messiaen L.M., Callens T., Roux K.J., Mortier G.R., De Paepe A.,
RA   Abramowicz M., Pericak-Vance M.A., Vance J.M., Wallace M.R.;
RT   "Exon 10b of the NF1 gene represents a mutational hotspot and harbors a
RT   recurrent missense mutation Y489C associated with aberrant splicing.";
RL   Genet. Med. 1:248-253(1999).
RN   [57]
RP   VARIANT NF1 PRO-1446.
RX   PubMed=10220149;
RX   DOI=10.1002/(sici)1098-1004(1999)13:4<337::aid-humu12>3.0.co;2-f;
RA   Peters H., Hess D., Fahsold R., Schuelke M.;
RT   "A novel mutation L1425P in the GAP-region of the NF1 gene detected by
RT   temperature gradient gel electrophoresis (TGGE).";
RL   Hum. Mutat. 13:337-337(1999).
RN   [58]
RP   VARIANTS NF1 PRO-216; PRO-357; CYS-491; PRO-549; THR-581; ARG-583; PHE-665;
RP   PRO-695; PRO-763; SER-777; LYS-780; PRO-781; PRO-847; SER-1156; PRO-1250;
RP   GLN-1276; PRO-1276; PRO-1446; VAL-1605 AND ILE-2507, AND VARIANT GLU-176.
RX   PubMed=10712197; DOI=10.1086/302809;
RA   Fahsold R., Hoffmeyer S., Mischung C., Gille C., Ehlers C.,
RA   Kuecuekceylan N., Abdel-Nour M., Gewies A., Peters H., Kaufmann D.,
RA   Buske A., Tinschert S., Nuernberg P.;
RT   "Minor lesion mutational spectrum of the entire NF1 gene does not explain
RT   its high mutability but points to a functional domain upstream of the GAP-
RT   related domain.";
RL   Am. J. Hum. Genet. 66:790-818(2000).
RN   [59]
RP   VARIANTS NF1 SER-117; TRP-1204; PRO-1446 AND 2387-ASN-PHE-2388 DEL.
RX   PubMed=10607834; DOI=10.1093/hmg/9.2.237;
RA   Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.;
RT   "Mutations affecting mRNA splicing are the most common molecular defects in
RT   patients with neurofibromatosis type 1.";
RL   Hum. Mol. Genet. 9:237-247(2000).
RN   [60]
RP   ERRATUM OF PUBMED:10607834.
RA   Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.;
RL   Hum. Mol. Genet. 9:659-659(2000).
RN   [61]
RP   VARIANT NF1 PHE-844.
RX   PubMed=10980545;
RX   DOI=10.1002/1098-1004(200009)16:3<274::aid-humu21>3.3.co;2-6;
RA   Boulandet E.G., Pantel J., Cazeneuve C., Van Gijn M., Vidaud D., Lemay S.,
RA   Martin J., Zeller J., Revuz J., Goossens M., Amselem S., Wolkenstein P.;
RT   "NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients
RT   with neurofibromatosis type 1.";
RL   Hum. Mutat. 16:274-275(2000).
RN   [62]
RP   VARIANT SPINAL FSNF PRO-2088.
RX   PubMed=11704931; DOI=10.1086/324648;
RA   Kaufmann D., Mueller R., Bartelt B., Wolf M., Kunzi-Rapp K., Hanemann C.O.,
RA   Fahsold R., Hein C., Vogel W., Assum G.;
RT   "Spinal neurofibromatosis without cafe-au-lait macules in two families with
RT   null mutations of the NF1 gene.";
RL   Am. J. Hum. Genet. 69:1395-1400(2001).
RN   [63]
RP   VARIANTS NF1 LYS-780; CYS-784; PRO-1147; CYS-1193; ARG-1444; SER-1785;
RP   ASN-2012 AND LYS-2357.
RX   PubMed=11735023; DOI=10.1007/s004390100594;
RA   Han S.S., Cooper D.N., Upadhyaya M.N.;
RT   "Evaluation of denaturing high performance liquid chromatography (DHPLC)
RT   for the mutational analysis of the neurofibromatosis type 1 (NF1) gene.";
RL   Hum. Genet. 109:487-497(2001).
RN   [64]
RP   VARIANTS NF1 PHE-82; ARG-784 AND GLU-1444.
RX   PubMed=11857752; DOI=10.1002/humu.9018;
RA   Kluwe L., Friedrich R.E., Korf B., Fahsold R., Mautner V.-F.;
RT   "NF1 mutations in neurofibromatosis 1 patients with plexiform
RT   neurofibromas.";
RL   Hum. Mutat. 19:309-309(2002).
RN   [65]
RP   VARIANT NFNS GLU-1459 DEL.
RX   PubMed=12707950; DOI=10.1002/ajmg.a.20023;
RA   Baralle D., Mattocks C., Kalidas K., Elmslie F., Whittaker J., Lees M.,
RA   Ragge N., Patton M.A., Winter R.M., ffrench-Constant C.;
RT   "Different mutations in the NF1 gene are associated with neurofibromatosis-
RT   Noonan syndrome (NFNS).";
RL   Am. J. Med. Genet. A 119:1-8(2003).
RN   [66]
RP   VARIANTS NF1 TYR-93; VAL-604; ARG-844 AND PRO-898, AND VARIANTS ASP-74;
RP   GLU-176; ARG-712 AND GLN-1276.
RX   PubMed=12522551; DOI=10.1007/s00439-002-0858-4;
RA   Wang Q., Montmain G., Ruano E., Upadhyaya M., Dudley S., Liskay R.M.,
RA   Thibodeau S.N., Puisieux A.;
RT   "Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-
RT   deficient cell type.";
RL   Hum. Genet. 112:117-123(2003).
RN   [67]
RP   VARIANTS NF1 LYS-780; PRO-847; GLU-848 AND ARG-968; ASN-1444; LEU-1953 DEL
RP   AND ARG-2001.
RX   PubMed=12552569; DOI=10.1002/humu.9111;
RA   De Luca A., Buccino A., Gianni D., Mangino M., Giustini S., Richetta A.,
RA   Divona L., Calvieri S., Mingarelli R., Dallapiccola B.;
RT   "NF1 gene analysis based on DHPLC.";
RL   Hum. Mutat. 21:171-172(2003).
RN   [68]
RP   VARIANTS NF1 ARG-578; PRO-920 AND ALA-2221.
RX   PubMed=12746402; DOI=10.1136/jmg.40.5.368;
RA   Kluwe L., Tatagiba M., Fuensterer C., Mautner V.F.;
RT   "NF1 mutations and clinical spectrum in patients with spinal
RT   neurofibromas.";
RL   J. Med. Genet. 40:368-371(2003).
RN   [69]
RP   VARIANT NF1 VAL-186, AND CHARACTERIZATION OF VARIANT NF1 VAL-186.
RX   PubMed=15523642; DOI=10.1002/humu.20103;
RA   Zatkova A., Messiaen L., Vandenbroucke I., Wieser R., Fonatsch C.,
RA   Krainer A.R., Wimmer K.;
RT   "Disruption of exonic splicing enhancer elements is the principal cause of
RT   exon skipping associated with seven nonsense or missense alleles of NF1.";
RL   Hum. Mutat. 24:491-501(2004).
RN   [70]
RP   VARIANTS NF1 ASN-157; ARG-629; SER-777; LYS-780; ARG-784; PRO-847; GLU-848;
RP   ARG-968; ASN-1444; LEU-1953 DEL AND ARG-2001, AND VARIANT GLU-176.
RX   PubMed=15146469; DOI=10.1002/humu.9245;
RA   De Luca A., Schirinzi A., Buccino A., Bottillo I., Sinibaldi L.,
RA   Torrente I., Ciavarella A., Dottorini T., Porciello R., Giustini S.,
RA   Calvieri S., Dallapiccola B.;
RT   "Novel and recurrent mutations in the NF1 gene in Italian patients with
RT   neurofibromatosis type 1.";
RL   Hum. Mutat. 23:629-629(2004).
RN   [71]
RP   VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532; ARG-574;
RP   ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073; ARG-1196;
RP   GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489, AND VARIANTS
RP   GLU-176 AND CYS-873.
RX   PubMed=15060124; DOI=10.1136/jmg.2003.011890;
RA   Mattocks C., Baralle D., Tarpey P., ffrench-Constant C., Bobrow M.,
RA   Whittaker J.;
RT   "Automated comparative sequence analysis identifies mutations in 89% of NF1
RT   patients and confirms a mutation cluster in exons 11-17 distinct from the
RT   GAP related domain.";
RL   J. Med. Genet. 41:E48-E48(2004).
RN   [72]
RP   VARIANT NF1 PRO-1243.
RX   PubMed=15520408; DOI=10.1136/jmg.2004.021683;
RA   Ferner R.E., Hughes R.A.C., Hall S.M., Upadhyaya M., Johnson M.R.;
RT   "Neurofibromatous neuropathy in neurofibromatosis 1 (NF1).";
RL   J. Med. Genet. 41:837-841(2004).
RN   [73]
RP   VARIANT NF1 ARG-844.
RX   PubMed=15948193; DOI=10.1002/ajmg.a.30813;
RA   Bertola D.R., Pereira A.C., Passetti F., de Oliveira P.S.L., Messiaen L.,
RA   Gelb B.D., Kim C.A., Krieger J.E.;
RT   "Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence
RT   of both disorders in a patient.";
RL   Am. J. Med. Genet. A 136:242-245(2005).
RN   [74]
RP   VARIANTS NFNS ARG-194; GLU-1444; THR-1451; LEU-1453 AND GLU-1459 DEL.
RX   PubMed=16380919; DOI=10.1086/498454;
RA   De Luca A., Bottillo I., Sarkozy A., Carta C., Neri C., Bellacchio E.,
RA   Schirinzi A., Conti E., Zampino G., Battaglia A., Majore S., Rinaldi M.M.,
RA   Carella M., Marino B., Pizzuti A., Digilio M.C., Tartaglia M.,
RA   Dallapiccola B.;
RT   "NF1 gene mutations represent the major molecular event underlying
RT   neurofibromatosis-Noonan syndrome.";
RL   Am. J. Hum. Genet. 77:1092-1101(2005).
RN   [75]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-1187; LEU-1951 AND ARG-2745.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [76]
RP   VARIANT NF1 MET-991 DEL.
RX   PubMed=17160901; DOI=10.1086/510781;
RA   Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N.,
RA   Giovannini S., Evans D.G., Howard E., Kerr B., Griffiths S., Consoli C.,
RA   Side L., Adams D., Pierpont M., Hachen R., Barnicoat A., Li H., Wallace P.,
RA   Van Biervliet J.P., Stevenson D., Viskochil D., Baralle D., Haan E.,
RA   Riccardi V., Turnpenny P., Lazaro C., Messiaen L.;
RT   "An absence of cutaneous neurofibromas associated with a 3-bp inframe
RT   deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a
RT   clinically significant NF1 genotype-phenotype correlation.";
RL   Am. J. Hum. Genet. 80:140-151(2007).
RN   [77]
RP   VARIANT NFNS PHE-1411.
RX   PubMed=19845691; DOI=10.1111/j.1399-0004.2009.01233.x;
RA   Nystrom A.M., Ekvall S., Allanson J., Edeby C., Elinder M., Holmstrom G.,
RA   Bondeson M.L., Anneren G.;
RT   "Noonan syndrome and neurofibromatosis type I in a family with a novel
RT   mutation in NF1.";
RL   Clin. Genet. 76:524-534(2009).
RN   [78]
RP   VARIANT NF1 THR-160.
RX   PubMed=21838856; DOI=10.1186/1897-4287-9-6;
RA   Ponti G., Losi L., Martorana D., Priola M., Boni E., Pollio A., Neri T.M.,
RA   Seidenari S.;
RT   "Clinico-pathological and biomolecular findings in Italian patients with
RT   multiple cutaneous neurofibromas.";
RL   Hered. Cancer Clin. Pract. 9:6-6(2011).
RN   [79]
RP   VARIANTS GLU-176; THR-330; ASP-393; LEU-393; PRO-519; THR-776 AND PHE-1484.
RX   PubMed=22108604; DOI=10.1038/ejhg.2011.207;
RA   Thomas L., Spurlock G., Eudall C., Thomas N.S., Mort M., Hamby S.E.,
RA   Chuzhanova N., Brems H., Legius E., Cooper D.N., Upadhyaya M.;
RT   "Exploring the somatic NF1 mutational spectrum associated with NF1
RT   cutaneous neurofibromas.";
RL   Eur. J. Hum. Genet. 20:411-419(2012).
RN   [80]
RP   VARIANTS NF1 TRP-93; ARG-1048; ARG-1189; ARG-1661 (ISOFORM I) AND THR-1918
RP   (ISOFORM I).
RX   PubMed=23758643; DOI=10.1111/ahg.12026;
RA   Nemethova M., Bolcekova A., Ilencikova D., Durovcikova D., Hlinkova K.,
RA   Hlavata A., Kovacs L., Kadasi L., Zatkova A.;
RT   "Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in
RT   Slovak patients.";
RL   Ann. Hum. Genet. 77:364-379(2013).
RN   [81]
RP   VARIANT NF1 PRO-2125.
RX   PubMed=24413922; DOI=10.1007/s00381-013-2352-9;
RA   Ben-Salem S., Al-Shamsi A.M., Ali B.R., Al-Gazali L.;
RT   "The mutational spectrum of the NF1 gene in neurofibromatosis type I
RT   patients from UAE.";
RL   Childs Nerv. Syst. 30:1183-1189(2014).
CC   -!- FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater
CC       affinity for Ras GAP, but lower specific activity. May be a regulator
CC       of Ras activity. {ECO:0000269|PubMed:2121371,
CC       ECO:0000269|PubMed:8417346}.
CC   -!- SUBUNIT: Interacts with HTR6 (PubMed:23027611). Interacts with SPRED2
CC       (PubMed:34626534). {ECO:0000269|PubMed:23027611,
CC       ECO:0000269|PubMed:34626534}.
CC   -!- INTERACTION:
CC       P21359; P05067: APP; NbExp=3; IntAct=EBI-1172917, EBI-77613;
CC       P21359; P01112: HRAS; NbExp=3; IntAct=EBI-1172917, EBI-350145;
CC       P21359; P34741: SDC2; NbExp=4; IntAct=EBI-1172917, EBI-1172957;
CC       P21359; Q7Z699: SPRED1; NbExp=6; IntAct=EBI-1172917, EBI-5235340;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14988005}. Nucleus,
CC       nucleolus {ECO:0000269|PubMed:14988005}. Cell membrane
CC       {ECO:0000269|PubMed:34626534}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Experimental confirmation may be lacking for some isoforms.;
CC       Name=II {ECO:0000303|PubMed:1923522};
CC         IsoId=P21359-1; Sequence=Displayed;
CC       Name=I {ECO:0000303|PubMed:1923522};
CC         IsoId=P21359-2; Sequence=VSP_001628;
CC       Name=3;
CC         IsoId=P21359-3; Sequence=VSP_001629, VSP_001630;
CC       Name=4;
CC         IsoId=P21359-4; Sequence=VSP_001631, VSP_001632;
CC       Name=5;
CC         IsoId=P21359-5; Sequence=VSP_043467, VSP_043468;
CC       Name=6;
CC         IsoId=P21359-6; Sequence=VSP_001628, VSP_053587;
CC   -!- TISSUE SPECIFICITY: Detected in brain, peripheral nerve, lung, colon
CC       and muscle. {ECO:0000269|PubMed:8417346}.
CC   -!- DOMAIN: Binds phospholipids via its C-terminal CRAL-TRIO domain. Binds
CC       primarily glycerophospholipids with monounsaturated C18:1 and/or C16:1
CC       fatty acid moieties and a phosphatidylethanolamine or
CC       phosphatidylcholine headgroup. Has lesser affinity for lipids
CC       containing phosphatidylserine and phosphatidylinositol.
CC       {ECO:0000269|PubMed:16397625, ECO:0000269|PubMed:17187824,
CC       ECO:0000269|PubMed:21089070}.
CC   -!- PTM: Ubiquitinated by RNF7/RBX2, leading to its degradation.
CC       {ECO:0000250|UniProtKB:Q04690}.
CC   -!- RNA EDITING: Modified_positions=1306 {ECO:0000269|PubMed:11727199,
CC       ECO:0000269|PubMed:8602361}; Note=The stop codon (UGA) at position 1306
CC       is created by RNA editing. Various levels of RNA editing occurs in
CC       peripheral nerve-sheath tumor samples (PNSTs) from patients with NF1.
CC       Preferentially observed in transcripts containing exon 23A.;
CC   -!- DISEASE: Neurofibromatosis 1 (NF1) [MIM:162200]: A disease
CC       characterized by patches of skin pigmentation (cafe-au-lait spots),
CC       Lisch nodules of the iris, tumors in the peripheral nervous system and
CC       fibromatous skin tumors. Individuals with the disorder have increased
CC       susceptibility to the development of benign and malignant tumors.
CC       {ECO:0000269|PubMed:10220149, ECO:0000269|PubMed:10336779,
CC       ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197,
CC       ECO:0000269|PubMed:10980545, ECO:0000269|PubMed:11258625,
CC       ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:11857752,
CC       ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:12552569,
CC       ECO:0000269|PubMed:12746402, ECO:0000269|PubMed:1302608,
CC       ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:15146469,
CC       ECO:0000269|PubMed:15520408, ECO:0000269|PubMed:15523642,
CC       ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:17160901,
CC       ECO:0000269|PubMed:21089070, ECO:0000269|PubMed:2114220,
CC       ECO:0000269|PubMed:21838856, ECO:0000269|PubMed:23758643,
CC       ECO:0000269|PubMed:24413922, ECO:0000269|PubMed:7981679,
CC       ECO:0000269|PubMed:8081387, ECO:0000269|PubMed:8544190,
CC       ECO:0000269|PubMed:8807336, ECO:0000269|PubMed:8834249,
CC       ECO:0000269|PubMed:9003501, ECO:0000269|PubMed:9101300,
CC       ECO:0000269|PubMed:9150739, ECO:0000269|PubMed:9298829,
CC       ECO:0000269|PubMed:9668168}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An
CC       aggressive pediatric myelodysplastic syndrome/myeloproliferative
CC       disorder characterized by malignant transformation in the hematopoietic
CC       stem cell compartment with proliferation of differentiated progeny.
CC       Patients have splenomegaly, enlarged lymph nodes, rashes, and
CC       hemorrhages. Note=The disease is caused by variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Watson syndrome (WTSN) [MIM:193520]: A syndrome characterized
CC       by the presence of pulmonary stenosis, cafe-au-lait spots, and
CC       intellectual disability. It is considered as an atypical form of
CC       neurofibromatosis. Note=The disease is caused by variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Familial spinal neurofibromatosis (FSNF) [MIM:162210]:
CC       Considered to be an alternative form of neurofibromatosis, showing
CC       multiple spinal tumors. {ECO:0000269|PubMed:11704931}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]:
CC       Characterized by manifestations of both NF1 and Noonan syndrome (NS).
CC       NS is a disorder characterized by dysmorphic facial features, short
CC       stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a
CC       bleeding diathesis. {ECO:0000269|PubMed:12707950,
CC       ECO:0000269|PubMed:16380919, ECO:0000269|PubMed:19845691}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of the
CC       large intestine (the colon) and the rectum. Genetic alterations are
CC       often associated with progression from premalignant lesion (adenoma) to
CC       invasive adenocarcinoma. Risk factors for cancer of the colon and
CC       rectum include colon polyps, long-standing ulcerative colitis, and
CC       genetic family history. Note=The gene represented in this entry may be
CC       involved in disease pathogenesis.
CC   -!- CAUTION: Was originally thought to be associated with LEOPARD (LS), an
CC       autosomal dominant syndrome. {ECO:0000305|PubMed:8807336}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59923.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/134/NF1";
CC   -!- WEB RESOURCE: Name=Mendelian genes neurofibromin 1 (NF1); Note=Leiden
CC       Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/NF1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M89914; AAA59925.1; -; mRNA.
DR   EMBL; M82814; AAA59924.1; -; mRNA.
DR   EMBL; M60496; AAA59928.1; -; mRNA.
DR   EMBL; D12625; BAA02150.1; -; mRNA.
DR   EMBL; M38106; AAA74897.1; -; mRNA.
DR   EMBL; M38107; AAB59558.1; -; mRNA.
DR   EMBL; D42072; BAA07669.1; -; mRNA.
DR   EMBL; AY796305; AAV50004.1; -; Genomic_DNA.
DR   EMBL; AC004222; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC134669; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC135724; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC138207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC139072; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471147; EAW80272.1; -; Genomic_DNA.
DR   EMBL; CH471147; EAW80275.1; -; Genomic_DNA.
DR   EMBL; AH000834; AAA18483.1; -; Genomic_DNA.
DR   EMBL; Y07853; CAA69179.1; -; Genomic_DNA.
DR   EMBL; U17690; AAB48380.1; -; Genomic_DNA.
DR   EMBL; U17680; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17681; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17682; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17683; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17684; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17685; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17686; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17687; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17688; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17689; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17690; AAB48379.1; -; Genomic_DNA.
DR   EMBL; U17680; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17681; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17682; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17683; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17684; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17685; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17687; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17688; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17689; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17656; AAB48373.1; -; Genomic_DNA.
DR   EMBL; U17659; AAB48374.1; -; Genomic_DNA.
DR   EMBL; U17662; AAB48375.1; -; Genomic_DNA.
DR   EMBL; U17668; AAB48376.1; -; Genomic_DNA.
DR   EMBL; U17667; AAB48376.1; JOINED; Genomic_DNA.
DR   EMBL; U17673; AAB48377.1; -; Genomic_DNA.
DR   EMBL; U17677; AAB48378.1; -; Genomic_DNA.
DR   EMBL; U17676; AAB48378.1; JOINED; Genomic_DNA.
DR   EMBL; M60915; AAA59921.1; -; mRNA.
DR   EMBL; M60915; AAA59922.1; -; mRNA.
DR   EMBL; M61213; AAA59923.1; ALT_INIT; mRNA.
DR   EMBL; S51751; AAB24636.1; -; mRNA.
DR   EMBL; D10490; BAA01371.1; -; mRNA.
DR   CCDS; CCDS11264.1; -. [P21359-2]
DR   CCDS; CCDS42292.1; -. [P21359-1]
DR   CCDS; CCDS45645.1; -. [P21359-5]
DR   PIR; B55282; B55282.
DR   PIR; I78852; I78852.
DR   RefSeq; NP_000258.1; NM_000267.3. [P21359-2]
DR   RefSeq; NP_001035957.1; NM_001042492.3. [P21359-1]
DR   RefSeq; NP_001121619.1; NM_001128147.3. [P21359-5]
DR   PDB; 1NF1; X-ray; 2.50 A; A=1198-1551.
DR   PDB; 2D4Q; X-ray; 2.30 A; A/B=1581-1837.
DR   PDB; 2E2X; X-ray; 2.50 A; A/B=1566-1837.
DR   PDB; 3P7Z; X-ray; 2.65 A; A/B=1566-1837.
DR   PDB; 3PEG; X-ray; 2.52 A; A=1566-1837.
DR   PDB; 3PG7; X-ray; 2.19 A; A/B=1581-1837.
DR   PDB; 6OB2; X-ray; 2.85 A; B/D=1209-1484.
DR   PDB; 6OB3; X-ray; 2.10 A; B/D=1209-1484.
DR   PDB; 6V65; X-ray; 2.76 A; B=1203-1551.
DR   PDB; 6V6F; X-ray; 2.54 A; B=1203-1551.
DR   PDB; 7MOC; EM; 4.56 A; A/B=2-2839.
DR   PDB; 7MP5; EM; 5.60 A; A/B=2-2839.
DR   PDB; 7MP6; EM; 6.25 A; A/B=2-2839.
DR   PDB; 7PGP; EM; 3.10 A; F/N=1-2839.
DR   PDB; 7PGQ; EM; 3.50 A; F/N=1-2839.
DR   PDB; 7PGR; EM; 4.00 A; F/N=1-2839.
DR   PDB; 7PGS; EM; 3.40 A; F/N=1-2839.
DR   PDB; 7PGT; EM; 4.80 A; F/N=1-2839.
DR   PDB; 7PGU; EM; 3.30 A; F/N=1-2839.
DR   PDB; 7R03; EM; 3.60 A; A/B=1-2839.
DR   PDB; 7R04; EM; 3.70 A; A/B=1-2839.
DR   PDB; 8E20; EM; 3.60 A; A/B=1-2839.
DR   PDB; 8EDL; EM; 3.70 A; A=1-2839.
DR   PDB; 8EDM; EM; 3.60 A; A/B=1-2839.
DR   PDB; 8EDN; EM; 3.80 A; A=1-2839.
DR   PDB; 8EDO; EM; 3.40 A; A/B=1039-2302.
DR   PDBsum; 1NF1; -.
DR   PDBsum; 2D4Q; -.
DR   PDBsum; 2E2X; -.
DR   PDBsum; 3P7Z; -.
DR   PDBsum; 3PEG; -.
DR   PDBsum; 3PG7; -.
DR   PDBsum; 6OB2; -.
DR   PDBsum; 6OB3; -.
DR   PDBsum; 6V65; -.
DR   PDBsum; 6V6F; -.
DR   PDBsum; 7MOC; -.
DR   PDBsum; 7MP5; -.
DR   PDBsum; 7MP6; -.
DR   PDBsum; 7PGP; -.
DR   PDBsum; 7PGQ; -.
DR   PDBsum; 7PGR; -.
DR   PDBsum; 7PGS; -.
DR   PDBsum; 7PGT; -.
DR   PDBsum; 7PGU; -.
DR   PDBsum; 7R03; -.
DR   PDBsum; 7R04; -.
DR   PDBsum; 8E20; -.
DR   PDBsum; 8EDL; -.
DR   PDBsum; 8EDM; -.
DR   PDBsum; 8EDN; -.
DR   PDBsum; 8EDO; -.
DR   EMDB; EMD-13391; -.
DR   EMDB; EMD-13392; -.
DR   EMDB; EMD-13393; -.
DR   EMDB; EMD-13394; -.
DR   EMDB; EMD-13395; -.
DR   EMDB; EMD-13396; -.
DR   EMDB; EMD-14218; -.
DR   EMDB; EMD-14219; -.
DR   EMDB; EMD-23924; -.
DR   EMDB; EMD-23929; -.
DR   EMDB; EMD-23930; -.
DR   EMDB; EMD-27826; -.
DR   EMDB; EMD-28035; -.
DR   EMDB; EMD-28036; -.
DR   EMDB; EMD-28037; -.
DR   EMDB; EMD-28038; -.
DR   SMR; P21359; -.
DR   BioGRID; 110836; 227.
DR   CORUM; P21359; -.
DR   FunCoup; P21359; 3476.
DR   IntAct; P21359; 68.
DR   MINT; P21359; -.
DR   STRING; 9606.ENSP00000351015; -.
DR   GlyGen; P21359; 5 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; P21359; -.
DR   PhosphoSitePlus; P21359; -.
DR   SwissPalm; P21359; -.
DR   BioMuta; NF1; -.
DR   DMDM; 548350; -.
DR   CPTAC; CPTAC-1622; -.
DR   jPOST; P21359; -.
DR   MassIVE; P21359; -.
DR   PaxDb; 9606-ENSP00000351015; -.
DR   PeptideAtlas; P21359; -.
DR   ProteomicsDB; 53861; -. [P21359-1]
DR   ProteomicsDB; 53862; -. [P21359-2]
DR   ProteomicsDB; 53863; -. [P21359-3]
DR   ProteomicsDB; 53864; -. [P21359-4]
DR   ProteomicsDB; 53865; -. [P21359-5]
DR   Pumba; P21359; -.
DR   Antibodypedia; 3471; 480 antibodies from 39 providers.
DR   CPTC; P21359; 3 antibodies.
DR   DNASU; 4763; -.
DR   Ensembl; ENST00000356175.7; ENSP00000348498.3; ENSG00000196712.20. [P21359-2]
DR   Ensembl; ENST00000358273.9; ENSP00000351015.4; ENSG00000196712.20. [P21359-1]
DR   Ensembl; ENST00000431387.8; ENSP00000412921.4; ENSG00000196712.20. [P21359-5]
DR   Ensembl; ENST00000487476.5; ENSP00000491589.1; ENSG00000196712.20. [P21359-3]
DR   GeneID; 4763; -.
DR   KEGG; hsa:4763; -.
DR   MANE-Select; ENST00000358273.9; ENSP00000351015.4; NM_001042492.3; NP_001035957.1.
DR   UCSC; uc002hgf.3; human. [P21359-1]
DR   AGR; HGNC:7765; -.
DR   CTD; 4763; -.
DR   DisGeNET; 4763; -.
DR   GeneCards; NF1; -.
DR   GeneReviews; NF1; -.
DR   HGNC; HGNC:7765; NF1.
DR   HPA; ENSG00000196712; Low tissue specificity.
DR   MalaCards; NF1; -.
DR   MIM; 114500; phenotype.
DR   MIM; 162200; phenotype.
DR   MIM; 162210; phenotype.
DR   MIM; 193520; phenotype.
DR   MIM; 601321; phenotype.
DR   MIM; 607785; phenotype.
DR   MIM; 613113; gene.
DR   neXtProt; NX_P21359; -.
DR   OpenTargets; ENSG00000196712; -.
DR   Orphanet; 97685; 17q11 microdeletion syndrome.
DR   Orphanet; 139474; 17q11.2 microduplication syndrome.
DR   Orphanet; 99756; Alveolar rhabdomyosarcoma.
DR   Orphanet; 99757; Embryonal rhabdomyosarcoma.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 363700; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion.
DR   Orphanet; 638; Neurofibromatosis-Noonan syndrome.
DR   Orphanet; 293199; Pleomorphic rhabdomyosarcoma.
DR   PharmGKB; PA31572; -.
DR   VEuPathDB; HostDB:ENSG00000196712; -.
DR   eggNOG; KOG1826; Eukaryota.
DR   GeneTree; ENSGT00550000074797; -.
DR   HOGENOM; CLU_036305_0_0_1; -.
DR   InParanoid; P21359; -.
DR   OMA; TKEPYMF; -.
DR   OrthoDB; 28245at2759; -.
DR   PAN-GO; P21359; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; P21359; -.
DR   TreeFam; TF300302; -.
DR   PathwayCommons; P21359; -.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants.
DR   SignaLink; P21359; -.
DR   SIGNOR; P21359; -.
DR   BioGRID-ORCS; 4763; 62 hits in 1192 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   ChiTaRS; NF1; human.
DR   EvolutionaryTrace; P21359; -.
DR   GeneWiki; Neurofibromin_1; -.
DR   GenomeRNAi; 4763; -.
DR   Pharos; P21359; Tbio.
DR   PRO; PR:P21359; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P21359; protein.
DR   Bgee; ENSG00000196712; Expressed in colonic epithelium and 202 other cell types or tissues.
DR   ExpressionAtlas; P21359; baseline and differential.
DR   GO; GO:0030424; C:axon; IDA:HGNC-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:HGNC-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IDA:HGNC-UCL.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:HGNC-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IDA:UniProtKB.
DR   GO; GO:0008429; F:phosphatidylethanolamine binding; IDA:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:HGNC-UCL.
DR   GO; GO:0030325; P:adrenal gland development; ISS:HGNC-UCL.
DR   GO; GO:0021764; P:amygdala development; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:HGNC-UCL.
DR   GO; GO:0007420; P:brain development; ISS:HGNC-UCL.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; ISS:HGNC-UCL.
DR   GO; GO:0007154; P:cell communication; ISS:HGNC-UCL.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:HGNC-UCL.
DR   GO; GO:0050890; P:cognition; IMP:HGNC-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:HGNC-UCL.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:HGNC-UCL.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0021897; P:forebrain astrocyte development; ISS:HGNC-UCL.
DR   GO; GO:0048853; P:forebrain morphogenesis; ISS:HGNC-UCL.
DR   GO; GO:0061534; P:gamma-aminobutyric acid secretion, neurotransmission; IEA:Ensembl.
DR   GO; GO:0061535; P:glutamate secretion, neurotransmission; IEA:Ensembl.
DR   GO; GO:0048820; P:hair follicle maturation; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:HGNC-UCL.
DR   GO; GO:0001889; P:liver development; ISS:HGNC-UCL.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; ISS:HGNC-UCL.
DR   GO; GO:0033024; P:mast cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0070662; P:mast cell proliferation; IEA:Ensembl.
DR   GO; GO:0001656; P:metanephros development; ISS:HGNC-UCL.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; ISS:HGNC-UCL.
DR   GO; GO:0097529; P:myeloid leukocyte migration; IEA:Ensembl.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:MGI.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:MGI.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0002686; P:negative regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:MGI.
DR   GO; GO:0070667; P:negative regulation of mast cell proliferation; IEA:Ensembl.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; ISS:HGNC-UCL.
DR   GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:Ensembl.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:HGNC-UCL.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0042308; P:negative regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0035021; P:negative regulation of Rac protein signal transduction; IEA:Ensembl.
DR   GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:1900148; P:negative regulation of Schwann cell migration; IEA:Ensembl.
DR   GO; GO:0010626; P:negative regulation of Schwann cell proliferation; IEA:Ensembl.
DR   GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl.
DR   GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0098597; P:observational learning; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:HGNC-UCL.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:HGNC-UCL.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:HGNC-UCL.
DR   GO; GO:0043473; P:pigmentation; ISS:HGNC-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:HGNC-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0033027; P:positive regulation of mast cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:HGNC-UCL.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISS:HGNC-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; IMP:HGNC-UCL.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; IMP:HGNC-UCL.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:HGNC-UCL.
DR   GO; GO:0001952; P:regulation of cell-matrix adhesion; ISS:HGNC-UCL.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045685; P:regulation of glial cell differentiation; ISS:HGNC-UCL.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:1900271; P:regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; ISS:HGNC-UCL.
DR   GO; GO:0014044; P:Schwann cell development; ISS:HGNC-UCL.
DR   GO; GO:0036135; P:Schwann cell migration; IEA:Ensembl.
DR   GO; GO:0014010; P:Schwann cell proliferation; IEA:Ensembl.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0048745; P:smooth muscle tissue development; ISS:HGNC-UCL.
DR   GO; GO:0021510; P:spinal cord development; ISS:HGNC-UCL.
DR   GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:HGNC-UCL.
DR   GO; GO:1904738; P:vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1990874; P:vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; ISS:HGNC-UCL.
DR   GO; GO:0042060; P:wound healing; ISS:HGNC-UCL.
DR   CDD; cd13313; PH_NF1; 1.
DR   CDD; cd05130; RasGAP_Neurofibromin; 1.
DR   CDD; cd00170; SEC14; 1.
DR   FunFam; 2.30.29.30:FF:000070; Neurofibromin 1; 1.
DR   FunFam; 3.40.525.10:FF:000004; Neurofibromin 1; 1.
DR   FunFam; 1.10.506.10:FF:000015; Neurofibromin isoform 1; 1.
DR   FunFam; 1.10.506.10:FF:000023; Neurofibromin isoform 1; 1.
DR   Gene3D; 3.40.525.10; CRAL-TRIO lipid binding domain; 1.
DR   Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR036865; CRAL-TRIO_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR054071; PH_NF1.
DR   InterPro; IPR039360; Ras_GTPase.
DR   InterPro; IPR023152; RasGAP_CS.
DR   InterPro; IPR001936; RasGAP_dom.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   PANTHER; PTHR10194:SF142; NEUROFIBROMIN; 1.
DR   PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1.
DR   Pfam; PF13716; CRAL_TRIO_2; 1.
DR   Pfam; PF21877; PH_NF1; 1.
DR   Pfam; PF00616; RasGAP; 1.
DR   SMART; SM00323; RasGAP; 1.
DR   SMART; SM00516; SEC14; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF48350; GTPase activation domain, GAP; 1.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1.
DR   PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane;
KW   Disease variant; GTPase activation; Lipid-binding; Membrane; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome; RNA editing;
KW   Tumor suppressor; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P97526"
FT   CHAIN           2..2839
FT                   /note="Neurofibromin"
FT                   /id="PRO_0000010773"
FT   CHAIN           2..1305
FT                   /note="Neurofibromin truncated"
FT                   /id="PRO_0000010774"
FT   DOMAIN          1251..1482
FT                   /note="Ras-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   DOMAIN          1580..1738
FT                   /note="CRAL-TRIO"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00056"
FT   REGION          1580..1837
FT                   /note="Lipid binding"
FT   REGION          2787..2839
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           2555..2571
FT                   /note="Bipartite nuclear localization signal"
FT   COMPBIAS        2801..2827
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            1276
FT                   /note="Arginine finger; crucial for GTP hydrolysis by
FT                   stabilizing the transition state"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P97526"
FT   MOD_RES         864
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         876
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2188
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2467
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q04690"
FT   MOD_RES         2514
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q04690"
FT   MOD_RES         2515
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2543
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         2565
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2597
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2802
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2817
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         548..551
FT                   /note="ALLV -> VRGK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1339276"
FT                   /id="VSP_001629"
FT   VAR_SEQ         552..2839
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1339276"
FT                   /id="VSP_001630"
FT   VAR_SEQ         574..593
FT                   /note="SSQMLFYICKKLTSHQMLSS -> RYMYFYFLNSTFKFYFVFLS (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:7570581"
FT                   /id="VSP_043467"
FT   VAR_SEQ         594..2839
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:7570581"
FT                   /id="VSP_043468"
FT   VAR_SEQ         1371..1391
FT                   /note="Missing (in isoform I and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:1457041,
FT                   ECO:0000303|PubMed:1783401, ECO:0000303|PubMed:1923522,
FT                   ECO:0000303|PubMed:2114220, ECO:0000303|PubMed:2116237,
FT                   ECO:0000303|PubMed:2134734"
FT                   /id="VSP_001628"
FT   VAR_SEQ         1591..1598
FT                   /note="SIFYQAGT -> TPPPEPET (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:2121370"
FT                   /id="VSP_001631"
FT   VAR_SEQ         1599..2839
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:2121370"
FT                   /id="VSP_001632"
FT   VAR_SEQ         2792
FT                   /note="P -> PASLPCSNSAVFMQLFPHQ (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:2116237"
FT                   /id="VSP_053587"
FT   VARIANT         31
FT                   /note="H -> R (in NF1; dbSNP:rs199474725)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032459"
FT   VARIANT         74
FT                   /note="A -> D (in mismatch repair deficient cancer cells;
FT                   dbSNP:rs199474726)"
FT                   /evidence="ECO:0000269|PubMed:12522551"
FT                   /id="VAR_017550"
FT   VARIANT         80
FT                   /note="Y -> C (in dbSNP:rs4795581)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022254"
FT   VARIANT         80
FT                   /note="Y -> S (in dbSNP:rs4795581)"
FT                   /id="VAR_049135"
FT   VARIANT         82
FT                   /note="S -> F (in NF1; dbSNP:rs199474729)"
FT                   /evidence="ECO:0000269|PubMed:11857752"
FT                   /id="VAR_021730"
FT   VARIANT         93
FT                   /note="C -> W (in NF1; dbSNP:rs1597629882)"
FT                   /evidence="ECO:0000269|PubMed:23758643"
FT                   /id="VAR_071668"
FT   VARIANT         93
FT                   /note="C -> Y (in NF1; dbSNP:rs199474728)"
FT                   /evidence="ECO:0000269|PubMed:12522551"
FT                   /id="VAR_017551"
FT   VARIANT         117
FT                   /note="I -> S (in NF1; dbSNP:rs199474731)"
FT                   /evidence="ECO:0000269|PubMed:10607834"
FT                   /id="VAR_010989"
FT   VARIANT         145
FT                   /note="L -> P (in NF1; dbSNP:rs199474734)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032460"
FT   VARIANT         157
FT                   /note="I -> N (in NF1; dbSNP:rs199474744)"
FT                   /evidence="ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021731"
FT   VARIANT         160
FT                   /note="R -> T (in NF1; dbSNP:rs199474752)"
FT                   /evidence="ECO:0000269|PubMed:21838856"
FT                   /id="VAR_065888"
FT   VARIANT         176
FT                   /note="D -> E (found in mismatch repair deficient cancer
FT                   cells; also found in a cutaneous neurofibroma from a
FT                   patient with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs112306990)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124,
FT                   ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:22108604"
FT                   /id="VAR_017552"
FT   VARIANT         186
FT                   /note="D -> V (in NF1; reduced splicing enhancement;
FT                   dbSNP:rs1567820771)"
FT                   /evidence="ECO:0000269|PubMed:15523642"
FT                   /id="VAR_032461"
FT   VARIANT         194
FT                   /note="L -> R (in NFNS; dbSNP:rs199474753)"
FT                   /evidence="ECO:0000269|PubMed:16380919"
FT                   /id="VAR_032462"
FT   VARIANT         216
FT                   /note="L -> P (in NF1; dbSNP:rs199474756)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021732"
FT   VARIANT         324
FT                   /note="C -> R (in NF1; dbSNP:rs199474735)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032463"
FT   VARIANT         330
FT                   /note="A -> T (in a cutaneous neurofibroma from a patient
FT                   with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs199474767)"
FT                   /evidence="ECO:0000269|PubMed:22108604"
FT                   /id="VAR_067201"
FT   VARIANT         337
FT                   /note="E -> V (in NF1; dbSNP:rs199474736)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032464"
FT   VARIANT         338
FT                   /note="D -> G (in NF1; dbSNP:rs199474773)"
FT                   /evidence="ECO:0000269|PubMed:9298829"
FT                   /id="VAR_010990"
FT   VARIANT         357
FT                   /note="L -> P (in NF1; dbSNP:rs137854563)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021733"
FT   VARIANT         393
FT                   /note="H -> D (in a cutaneous neurofibroma from a patient
FT                   with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs199474768)"
FT                   /evidence="ECO:0000269|PubMed:22108604"
FT                   /id="VAR_067202"
FT   VARIANT         393
FT                   /note="H -> L (in a cutaneous neurofibroma from a patient
FT                   with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs199474769)"
FT                   /evidence="ECO:0000269|PubMed:22108604"
FT                   /id="VAR_067203"
FT   VARIANT         489
FT                   /note="Y -> C (in NF1; dbSNP:rs137854557)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032465"
FT   VARIANT         491
FT                   /note="Y -> C (in NF1; dbSNP:rs199474757)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021734"
FT   VARIANT         508
FT                   /note="L -> P (in NF1; dbSNP:rs137854558)"
FT                   /evidence="ECO:0000269|PubMed:11258625"
FT                   /id="VAR_010991"
FT   VARIANT         519
FT                   /note="Q -> P (in a cutaneous neurofibroma from a patient
FT                   with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs199474770)"
FT                   /evidence="ECO:0000269|PubMed:22108604"
FT                   /id="VAR_067204"
FT   VARIANT         532
FT                   /note="L -> P (in NF1; dbSNP:rs199474737)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032466"
FT   VARIANT         549
FT                   /note="L -> P (in NF1; dbSNP:rs199474758)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021735"
FT   VARIANT         574
FT                   /note="S -> R (in NF1; dbSNP:rs2144015494 and
FT                   dbSNP:rs2066929440)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032467"
FT   VARIANT         578
FT                   /note="L -> R (in NF1; dbSNP:rs199474774)"
FT                   /evidence="ECO:0000269|PubMed:12746402"
FT                   /id="VAR_021736"
FT   VARIANT         581
FT                   /note="I -> T (in NF1; dbSNP:rs199474759)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021737"
FT   VARIANT         583
FT                   /note="K -> R (in NF1; dbSNP:rs199474760)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021738"
FT   VARIANT         604
FT                   /note="L -> V (in NF1; dbSNP:rs142712751)"
FT                   /evidence="ECO:0000269|PubMed:12522551"
FT                   /id="VAR_017553"
FT   VARIANT         629
FT                   /note="G -> R (in NF1; affects splicing by creating a novel
FT                   splice acceptor site; dbSNP:rs199474738)"
FT                   /evidence="ECO:0000269|PubMed:15060124,
FT                   ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:8834249"
FT                   /id="VAR_002653"
FT   VARIANT         665
FT                   /note="S -> F (in NF1; uncertain significance;
FT                   dbSNP:rs145891889)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:15060124"
FT                   /id="VAR_021739"
FT   VARIANT         678
FT                   /note="P -> L (in dbSNP:rs17881753)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022255"
FT   VARIANT         695
FT                   /note="L -> P (in NF1; dbSNP:rs199474761)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021740"
FT   VARIANT         712
FT                   /note="H -> R (in mismatch repair deficient cancer cells;
FT                   dbSNP:rs199474727)"
FT                   /evidence="ECO:0000269|PubMed:12522551"
FT                   /id="VAR_017554"
FT   VARIANT         763
FT                   /note="L -> P (in NF1; dbSNP:rs199474762)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021741"
FT   VARIANT         765
FT                   /note="R -> H (in NF1; uncertain significance;
FT                   dbSNP:rs199474777)"
FT                   /evidence="ECO:0000269|PubMed:10336779"
FT                   /id="VAR_021742"
FT   VARIANT         776
FT                   /note="A -> T (in a cutaneous neurofibroma from a patient
FT                   with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs199474771)"
FT                   /evidence="ECO:0000269|PubMed:22108604"
FT                   /id="VAR_067205"
FT   VARIANT         777
FT                   /note="W -> S (in NF1; dbSNP:rs199474745)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021743"
FT   VARIANT         780
FT                   /note="T -> K (in NF1; dbSNP:rs199474746)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:12552569,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021744"
FT   VARIANT         781
FT                   /note="H -> P (in NF1; dbSNP:rs199474763)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021745"
FT   VARIANT         784
FT                   /note="W -> C (in NF1; dbSNP:rs199474778)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021746"
FT   VARIANT         784
FT                   /note="W -> R (in NF1; dbSNP:rs199474730)"
FT                   /evidence="ECO:0000269|PubMed:11857752,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021747"
FT   VARIANT         844
FT                   /note="L -> F (in NF1; dbSNP:rs199474785)"
FT                   /evidence="ECO:0000269|PubMed:10980545,
FT                   ECO:0000269|PubMed:15060124"
FT                   /id="VAR_010992"
FT   VARIANT         844
FT                   /note="L -> P (in NF1; dbSNP:rs137854566)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032468"
FT   VARIANT         844
FT                   /note="L -> R (in NF1; sporadic; dbSNP:rs137854566)"
FT                   /evidence="ECO:0000269|PubMed:12522551,
FT                   ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:9150739"
FT                   /id="VAR_002654"
FT   VARIANT         847
FT                   /note="L -> P (in NF1; dbSNP:rs199474747)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:12552569, ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021748"
FT   VARIANT         848
FT                   /note="G -> E (in NF1; dbSNP:rs199474748)"
FT                   /evidence="ECO:0000269|PubMed:12552569,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021749"
FT   VARIANT         873
FT                   /note="R -> C (in dbSNP:rs199474739)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032469"
FT   VARIANT         898
FT                   /note="L -> P (in NF1; sporadic; dbSNP:rs199474786)"
FT                   /evidence="ECO:0000269|PubMed:12522551,
FT                   ECO:0000269|PubMed:9150739"
FT                   /id="VAR_002655"
FT   VARIANT         920
FT                   /note="L -> P (in NF1; patient with cafe-au-lait spots; may
FT                   be a distinct form of NF1; dbSNP:rs199474775)"
FT                   /evidence="ECO:0000269|PubMed:12746402"
FT                   /id="VAR_021750"
FT   VARIANT         968
FT                   /note="M -> R (in NF1; dbSNP:rs199474749)"
FT                   /evidence="ECO:0000269|PubMed:12552569,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021751"
FT   VARIANT         991
FT                   /note="Missing (in NF1; most patients carrying the mutation
FT                   do not manifest cutaneous neurofibromas)"
FT                   /evidence="ECO:0000269|PubMed:15060124,
FT                   ECO:0000269|PubMed:17160901, ECO:0000269|PubMed:7904209"
FT                   /id="VAR_002656"
FT   VARIANT         1035
FT                   /note="M -> R (in NF1; dbSNP:rs137854553)"
FT                   /evidence="ECO:0000269|PubMed:8807336"
FT                   /id="VAR_002657"
FT   VARIANT         1048
FT                   /note="W -> R (in NF1; dbSNP:rs1555614634)"
FT                   /evidence="ECO:0000269|PubMed:23758643"
FT                   /id="VAR_071669"
FT   VARIANT         1073
FT                   /note="M -> V (in NF1; dbSNP:rs199474740)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032470"
FT   VARIANT         1147
FT                   /note="L -> P (in NF1; dbSNP:rs199474779)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021752"
FT   VARIANT         1156
FT                   /note="N -> S (in NF1; dbSNP:rs199474764)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021753"
FT   VARIANT         1166
FT                   /note="G -> D (in NF1; dbSNP:rs199474787)"
FT                   /evidence="ECO:0000269|PubMed:7981679"
FT                   /id="VAR_010993"
FT   VARIANT         1187
FT                   /note="L -> I (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs2067142260)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035543"
FT   VARIANT         1189
FT                   /note="Q -> R (in NF1; dbSNP:rs752039618)"
FT                   /evidence="ECO:0000269|PubMed:23758643"
FT                   /id="VAR_071670"
FT   VARIANT         1193
FT                   /note="F -> C (in NF1; dbSNP:rs199474780)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021754"
FT   VARIANT         1196
FT                   /note="L -> R (in NF1; dbSNP:rs199474741)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032471"
FT   VARIANT         1204
FT                   /note="R -> G (in NF1; dbSNP:rs199474732)"
FT                   /evidence="ECO:0000269|PubMed:10336779"
FT                   /id="VAR_021755"
FT   VARIANT         1204
FT                   /note="R -> W (in NF1; dbSNP:rs199474732)"
FT                   /evidence="ECO:0000269|PubMed:10607834"
FT                   /id="VAR_010994"
FT   VARIANT         1243
FT                   /note="L -> P (in NF1; with neurofibromatous neuropathy;
FT                   dbSNP:rs137854564)"
FT                   /evidence="ECO:0000269|PubMed:15520408"
FT                   /id="VAR_032472"
FT   VARIANT         1250
FT                   /note="R -> P (in NF1; dbSNP:rs199474765)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021756"
FT   VARIANT         1276
FT                   /note="R -> G (in NF1; dbSNP:rs199474742)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032473"
FT   VARIANT         1276
FT                   /note="R -> P (in NF1; complete loss of GAP activity;
FT                   dbSNP:rs137854556)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:9668168"
FT                   /id="VAR_010995"
FT   VARIANT         1276
FT                   /note="R -> Q (in NF1 and mismatch repair deficient cancer
FT                   cells; dbSNP:rs137854556)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124"
FT                   /id="VAR_017555"
FT   VARIANT         1411
FT                   /note="L -> F (in NFNS; dbSNP:rs199474789)"
FT                   /evidence="ECO:0000269|PubMed:19845691"
FT                   /id="VAR_065236"
FT   VARIANT         1412
FT                   /note="R -> S (in NF1; significant reduction of GAP
FT                   activity; dbSNP:rs137854554)"
FT                   /evidence="ECO:0000269|PubMed:9003501"
FT                   /id="VAR_010996"
FT   VARIANT         1422
FT                   /note="Y -> H (in dbSNP:rs17884349)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022256"
FT   VARIANT         1430
FT                   /note="K -> E (in NF1)"
FT                   /evidence="ECO:0000269|PubMed:15060124"
FT                   /id="VAR_032474"
FT   VARIANT         1440
FT                   /note="K -> Q (in NF1; dbSNP:rs199474790)"
FT                   /evidence="ECO:0000269|PubMed:9003501"
FT                   /id="VAR_010997"
FT   VARIANT         1440
FT                   /note="K -> R (in NF1; dbSNP:rs199474788)"
FT                   /evidence="ECO:0000269|PubMed:7981679"
FT                   /id="VAR_002658"
FT   VARIANT         1444
FT                   /note="K -> E (in NF1 and NFNS; significant reduction of
FT                   intrinsic GAP activity; dbSNP:rs137854550)"
FT                   /evidence="ECO:0000269|PubMed:11857752,
FT                   ECO:0000269|PubMed:1568247, ECO:0000269|PubMed:16380919,
FT                   ECO:0000269|PubMed:9003501"
FT                   /id="VAR_002659"
FT   VARIANT         1444
FT                   /note="K -> N (in NF1; dbSNP:rs199474750)"
FT                   /evidence="ECO:0000269|PubMed:12552569,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021757"
FT   VARIANT         1444
FT                   /note="K -> R (in NF1; dbSNP:rs199474781)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021758"
FT   VARIANT         1446
FT                   /note="L -> P (in NF1; dbSNP:rs199474733)"
FT                   /evidence="ECO:0000269|PubMed:10220149,
FT                   ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197"
FT                   /id="VAR_008129"
FT   VARIANT         1451
FT                   /note="N -> T (in NFNS; dbSNP:rs199474754)"
FT                   /evidence="ECO:0000269|PubMed:16380919"
FT                   /id="VAR_032475"
FT   VARIANT         1453
FT                   /note="V -> L (in NFNS; dbSNP:rs199474755)"
FT                   /evidence="ECO:0000269|PubMed:16380919"
FT                   /id="VAR_032476"
FT   VARIANT         1459
FT                   /note="Missing (in NFNS; dbSNP:rs267606607)"
FT                   /evidence="ECO:0000269|PubMed:12707950,
FT                   ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:16380919"
FT                   /id="VAR_032477"
FT   VARIANT         1484
FT                   /note="S -> F (in a cutaneous neurofibroma from a patient
FT                   with neurofibromatosis; somatic mutation;
FT                   dbSNP:rs199474772)"
FT                   /evidence="ECO:0000269|PubMed:22108604"
FT                   /id="VAR_067206"
FT   VARIANT         1489
FT                   /note="S -> G (in NF1; dbSNP:rs199474743)"
FT                   /evidence="ECO:0000269|PubMed:15060124,
FT                   ECO:0000269|PubMed:9003501"
FT                   /id="VAR_010998"
FT   VARIANT         1605
FT                   /note="I -> V (in NF1; reduces protein stability;
FT                   dbSNP:rs199474766)"
FT                   /evidence="ECO:0000269|PubMed:10712197,
FT                   ECO:0000269|PubMed:21089070"
FT                   /id="VAR_021759"
FT   VARIANT         1611
FT                   /note="R -> W (in NF1; dbSNP:rs1060500316)"
FT                   /evidence="ECO:0000269|PubMed:9298829"
FT                   /id="VAR_002660"
FT   VARIANT         1733
FT                   /note="L -> LGHEQQKLPAATLAL (in NF1)"
FT                   /evidence="ECO:0000269|PubMed:8317503"
FT                   /id="VAR_002661"
FT   VARIANT         1785
FT                   /note="A -> S (in NF1; dbSNP:rs199474782)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021760"
FT   VARIANT         1951
FT                   /note="P -> L (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs2151550343)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035544"
FT   VARIANT         1952
FT                   /note="W -> R (in NF1; dbSNP:rs199474791)"
FT                   /evidence="ECO:0000269|PubMed:9101300"
FT                   /id="VAR_002662"
FT   VARIANT         1953
FT                   /note="L -> P (in NF1; dbSNP:rs199474792)"
FT                   /evidence="ECO:0000269|PubMed:2114220"
FT                   /id="VAR_002663"
FT   VARIANT         1953
FT                   /note="Missing (in NF1)"
FT                   /evidence="ECO:0000269|PubMed:12552569,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021761"
FT   VARIANT         2001
FT                   /note="G -> R (in NF1; dbSNP:rs199474751)"
FT                   /evidence="ECO:0000269|PubMed:12552569,
FT                   ECO:0000269|PubMed:15146469"
FT                   /id="VAR_021762"
FT   VARIANT         2012
FT                   /note="D -> N (in NF1; dbSNP:rs199474783)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021763"
FT   VARIANT         2088
FT                   /note="L -> P (in FSNF; no cafe-au-lait macules; null
FT                   mutation; 50% reduction of protein level;
FT                   dbSNP:rs137854561)"
FT                   /evidence="ECO:0000269|PubMed:11704931"
FT                   /id="VAR_017669"
FT   VARIANT         2125
FT                   /note="L -> P (in NF1; dbSNP:rs1597843129)"
FT                   /evidence="ECO:0000269|PubMed:24413922"
FT                   /id="VAR_071671"
FT   VARIANT         2164
FT                   /note="L -> M (in NF1; dbSNP:rs137854551)"
FT                   /evidence="ECO:0000269|PubMed:1302608"
FT                   /id="VAR_002664"
FT   VARIANT         2192
FT                   /note="Y -> N (in NF1; dbSNP:rs267606598)"
FT                   /evidence="ECO:0000269|PubMed:1302608"
FT                   /id="VAR_002665"
FT   VARIANT         2221
FT                   /note="P -> A (in NF1; dbSNP:rs199474776)"
FT                   /evidence="ECO:0000269|PubMed:12746402"
FT                   /id="VAR_021764"
FT   VARIANT         2357
FT                   /note="E -> K (in NF1; dbSNP:rs199474784)"
FT                   /evidence="ECO:0000269|PubMed:11735023"
FT                   /id="VAR_021765"
FT   VARIANT         2387..2388
FT                   /note="Missing (in NF1)"
FT                   /evidence="ECO:0000269|PubMed:10607834,
FT                   ECO:0000269|PubMed:8081387"
FT                   /id="VAR_002666"
FT   VARIANT         2507
FT                   /note="T -> I (in NF1; dbSNP:rs149055633)"
FT                   /evidence="ECO:0000269|PubMed:10712197"
FT                   /id="VAR_021766"
FT   VARIANT         2511
FT                   /note="V -> L (in dbSNP:rs2230850)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_022257"
FT   VARIANT         2631
FT                   /note="T -> A (in NF1; dbSNP:rs199474793)"
FT                   /evidence="ECO:0000269|PubMed:8544190"
FT                   /id="VAR_002667"
FT   VARIANT         2745
FT                   /note="G -> R (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs2151587866)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035545"
FT   MUTAGEN         1691
FT                   /note="K->A: Reduces phospholipid binding; when associated
FT                   with A-1695; A-1769 and A-1771."
FT                   /evidence="ECO:0000269|PubMed:16397625"
FT   MUTAGEN         1695
FT                   /note="R->A: Reduces phospholipid binding; when associated
FT                   with A-1691; A-1769 and A-1771."
FT                   /evidence="ECO:0000269|PubMed:16397625"
FT   MUTAGEN         1769
FT                   /note="R->A: Reduces phospholipid binding; when associated
FT                   with A-1691; A-1695 and A-1771."
FT                   /evidence="ECO:0000269|PubMed:16397625"
FT   MUTAGEN         1771
FT                   /note="K->A: Reduces phospholipid binding; when associated
FT                   with A-1691; A-169 and A-1769."
FT                   /evidence="ECO:0000269|PubMed:16397625,
FT                   ECO:0000269|PubMed:21089070"
FT   MUTAGEN         1771
FT                   /note="Missing: Reduces protein stability."
FT                   /evidence="ECO:0000269|PubMed:16397625,
FT                   ECO:0000269|PubMed:21089070"
FT   CONFLICT        496
FT                   /note="M -> I (in Ref. 11; AAA74897/AAB59558)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1094..1095
FT                   /note="EL -> ST (in Ref. 14; AAA59923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1576
FT                   /note="H -> HH (in Ref. 11; AAA74897/AAB59558)"
FT                   /evidence="ECO:0000305"
FT   HELIX           5..18
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            31..33
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           34..46
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            47..49
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           51..66
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           73..96
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           106..111
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           114..121
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           130..146
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           150..166
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           174..181
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           187..201
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           206..226
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           228..236
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           240..256
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           260..276
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           278..285
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           294..307
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           314..331
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          336..338
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           341..357
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          360..362
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          367..371
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           373..386
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          387..389
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           394..398
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          399..402
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           404..419
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          424..426
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           429..435
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           436..454
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           483..502
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           505..508
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          516..518
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           522..530
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            531..534
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           539..551
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           555..558
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           559..561
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            566..568
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           569..587
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           593..617
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           678..691
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            693..696
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           700..708
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           711..720
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           724..727
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            728..730
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           735..745
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           752..762
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           763..765
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           771..793
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           832..846
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           849..851
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           890..899
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            900..903
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            907..909
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           910..923
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           927..929
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           930..942
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            947..949
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           955..973
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           979..983
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           989..1000
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1006..1021
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            1026..1028
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1034..1046
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1053..1056
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1060..1063
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1064..1080
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          1091..1093
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           1095..1116
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1135..1155
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1157..1160
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1162..1167
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1173..1190
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1197..1200
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   TURN            1201..1204
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           1208..1216
FT                   /evidence="ECO:0007829|PDB:1NF1"
FT   TURN            1217..1219
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           1220..1228
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1233..1235
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1236..1249
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1253..1267
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1271..1273
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   STRAND          1277..1279
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           1280..1309
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   TURN            1310..1312
FT                   /evidence="ECO:0007829|PDB:6V6F"
FT   HELIX           1315..1317
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1323..1325
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   STRAND          1328..1330
FT                   /evidence="ECO:0007829|PDB:6V65"
FT   HELIX           1332..1351
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1354..1356
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1359..1370
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1392..1394
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1398..1400
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1401..1411
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1414..1419
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   TURN            1421..1425
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   STRAND          1426..1429
FT                   /evidence="ECO:0007829|PDB:6V6F"
FT   HELIX           1433..1451
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1459..1464
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   HELIX           1465..1483
FT                   /evidence="ECO:0007829|PDB:6OB3"
FT   STRAND          1490..1492
FT                   /evidence="ECO:0007829|PDB:7PGU"
FT   HELIX           1510..1514
FT                   /evidence="ECO:0007829|PDB:1NF1"
FT   HELIX           1517..1520
FT                   /evidence="ECO:0007829|PDB:1NF1"
FT   HELIX           1531..1533
FT                   /evidence="ECO:0007829|PDB:7PGS"
FT   HELIX           1535..1544
FT                   /evidence="ECO:0007829|PDB:1NF1"
FT   HELIX           1569..1578
FT                   /evidence="ECO:0007829|PDB:3P7Z"
FT   TURN            1582..1586
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1587..1590
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1592..1598
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1604..1609
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1610..1612
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   TURN            1615..1617
FT                   /evidence="ECO:0007829|PDB:2D4Q"
FT   HELIX           1620..1631
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   TURN            1632..1636
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1639..1644
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1650..1652
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1656..1661
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   TURN            1662..1664
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1668..1672
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1674..1681
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1684..1692
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1694..1697
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   TURN            1698..1702
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1706..1711
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1714..1717
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1721..1723
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1728..1732
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1738..1749
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1751..1757
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1759..1767
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1770..1772
FT                   /evidence="ECO:0007829|PDB:2D4Q"
FT   STRAND          1775..1777
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1780..1784
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1785..1787
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1788..1795
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1798..1803
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   STRAND          1810..1813
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1817..1833
FT                   /evidence="ECO:0007829|PDB:3PG7"
FT   HELIX           1847..1849
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1851..1861
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1867..1884
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1906..1918
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1920..1922
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1923..1936
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1939..1949
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1950..1952
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1957..1960
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          1965..1967
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1968..1984
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           1989..2000
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2004..2006
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2007..2021
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2026..2041
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2043..2057
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2058..2060
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2069..2071
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2075..2089
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2090..2092
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2096..2108
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2109..2112
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2116..2134
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          2137..2139
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2143..2155
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2159..2165
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2173..2177
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2180..2184
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2199..2219
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2225..2237
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2242..2244
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2245..2250
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2252..2255
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2261..2280
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2285..2287
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2289..2301
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2302..2304
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2311..2314
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2317..2323
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2328..2347
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   STRAND          2351..2354
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2356..2363
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2365..2367
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2368..2378
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2382..2384
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2386..2392
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2393..2395
FT                   /evidence="ECO:0007829|PDB:7PGS"
FT   HELIX           2396..2399
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2403..2424
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2427..2429
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2434..2436
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2437..2441
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2443..2445
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2447..2452
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2607..2609
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2613..2629
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2633..2649
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2651..2653
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2654..2657
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2658..2671
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2675..2690
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2700..2702
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2704..2706
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   TURN            2709..2715
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   HELIX           2728..2742
FT                   /evidence="ECO:0007829|PDB:7PGP"
FT   VARIANT         P21359-2:1661
FT                   /note="C -> R (in NF1; dbSNP:rs1597829901)"
FT                   /evidence="ECO:0000269|PubMed:23758643"
FT                   /id="VAR_082822"
FT   VARIANT         P21359-2:1918
FT                   /note="I -> T (in NF1; dbSNP:rs1304057833)"
FT                   /evidence="ECO:0000269|PubMed:23758643"
FT                   /id="VAR_082823"
SQ   SEQUENCE   2839 AA;  319372 MW;  C079475139DBD51E CRC64;
     MAAHRPVEWV QAVVSRFDEQ LPIKTGQQNT HTKVSTEHNK ECLINISKYK FSLVISGLTT
     ILKNVNNMRI FGEAAEKNLY LSQLIILDTL EKCLAGQPKD TMRLDETMLV KQLLPEICHF
     LHTCREGNQH AAELRNSASG VLFSLSCNNF NAVFSRISTR LQELTVCSED NVDVHDIELL
     QYINVDCAKL KRLLKETAFK FKALKKVAQL AVINSLEKAF WNWVENYPDE FTKLYQIPQT
     DMAECAEKLF DLVDGFAEST KRKAAVWPLQ IILLILCPEI IQDISKDVVD ENNMNKKLFL
     DSLRKALAGH GGSRQLTESA AIACVKLCKA STYINWEDNS VIFLLVQSMV VDLKNLLFNP
     SKPFSRGSQP ADVDLMIDCL VSCFRISPHN NQHFKICLAQ NSPSTFHYVL VNSLHRIITN
     SALDWWPKID AVYCHSVELR NMFGETLHKA VQGCGAHPAI RMAPSLTFKE KVTSLKFKEK
     PTDLETRSYK YLLLSMVKLI HADPKLLLCN PRKQGPETQG STAELITGLV QLVPQSHMPE
     IAQEAMEALL VLHQLDSIDL WNPDAPVETF WEISSQMLFY ICKKLTSHQM LSSTEILKWL
     REILICRNKF LLKNKQADRS SCHFLLFYGV GCDIPSSGNT SQMSMDHEEL LRTPGASLRK
     GKGNSSMDSA AGCSGTPPIC RQAQTKLEVA LYMFLWNPDT EAVLVAMSCF RHLCEEADIR
     CGVDEVSVHN LLPNYNTFME FASVSNMMST GRAALQKRVM ALLRRIEHPT AGNTEAWEDT
     HAKWEQATKL ILNYPKAKME DGQAAESLHK TIVKRRMSHV SGGGSIDLSD TDSLQEWINM
     TGFLCALGGV CLQQRSNSGL ATYSPPMGPV SERKGSMISV MSSEGNADTP VSKFMDRLLS
     LMVCNHEKVG LQIRTNVKDL VGLELSPALY PMLFNKLKNT ISKFFDSQGQ VLLTDTNTQF
     VEQTIAIMKN LLDNHTEGSS EHLGQASIET MMLNLVRYVR VLGNMVHAIQ IKTKLCQLVE
     VMMARRDDLS FCQEMKFRNK MVEYLTDWVM GTSNQAADDD VKCLTRDLDQ ASMEAVVSLL
     AGLPLQPEEG DGVELMEAKS QLFLKYFTLF MNLLNDCSEV EDESAQTGGR KRGMSRRLAS
     LRHCTVLAMS NLLNANVDSG LMHSIGLGYH KDLQTRATFM EVLTKILQQG TEFDTLAETV
     LADRFERLVE LVTMMGDQGE LPIAMALANV VPCSQWDELA RVLVTLFDSR HLLYQLLWNM
     FSKEVELADS MQTLFRGNSL ASKIMTFCFK VYGATYLQKL LDPLLRIVIT SSDWQHVSFE
     VDPTRLEPSE SLEENQRNLL QMTEKFFHAI ISSSSEFPPQ LRSVCHCLYQ ATCHSLLNKA
     TVKEKKENKK SVVSQRFPQN SIGAVGSAMF LRFINPAIVS PYEAGILDKK PPPRIERGLK
     LMSKILQSIA NHVLFTKEEH MRPFNDFVKS NFDAARRFFL DIASDCPTSD AVNHSLSFIS
     DGNVLALHRL LWNNQEKIGQ YLSSNRDHKA VGRRPFDKMA TLLAYLGPPE HKPVADTHWS
     SLNLTSSKFE EFMTRHQVHE KEEFKALKTL SIFYQAGTSK AGNPIFYYVA RRFKTGQING
     DLLIYHVLLT LKPYYAKPYE IVVDLTHTGP SNRFKTDFLS KWFVVFPGFA YDNVSAVYIY
     NCNSWVREYT KYHERLLTGL KGSKRLVFID CPGKLAEHIE HEQQKLPAAT LALEEDLKVF
     HNALKLAHKD TKVSIKVGST AVQVTSAERT KVLGQSVFLN DIYYASEIEE ICLVDENQFT
     LTIANQGTPL TFMHQECEAI VQSIIHIRTR WELSQPDSIP QHTKIRPKDV PGTLLNIALL
     NLGSSDPSLR SAAYNLLCAL TCTFNLKIEG QLLETSGLCI PANNTLFIVS ISKTLAANEP
     HLTLEFLEEC ISGFSKSSIE LKHLCLEYMT PWLSNLVRFC KHNDDAKRQR VTAILDKLIT
     MTINEKQMYP SIQAKIWGSL GQITDLLDVV LDSFIKTSAT GGLGSIKAEV MADTAVALAS
     GNVKLVSSKV IGRMCKIIDK TCLSPTPTLE QHLMWDDIAI LARYMLMLSF NNSLDVAAHL
     PYLFHVVTFL VATGPLSLRA STHGLVINII HSLCTCSQLH FSEETKQVLR LSLTEFSLPK
     FYLLFGISKV KSAAVIAFRS SYRDRSFSPG SYERETFALT SLETVTEALL EIMEACMRDI
     PTCKWLDQWT ELAQRFAFQY NPSLQPRALV VFGCISKRVS HGQIKQIIRI LSKALESCLK
     GPDTYNSQVL IEATVIALTK LQPLLNKDSP LHKALFWVAV AVLQLDEVNL YSAGTALLEQ
     NLHTLDSLRI FNDKSPEEVF MAIRNPLEWH CKQMDHFVGL NFNSNFNFAL VGHLLKGYRH
     PSPAIVARTV RILHTLLTLV NKHRNCDKFE VNTQSVAYLA ALLTVSEEVR SRCSLKHRKS
     LLLTDISMEN VPMDTYPIHH GDPSYRTLKE TQPWSSPKGS EGYLAATYPT VGQTSPRARK
     SMSLDMGQPS QANTKKLLGT RKSFDHLISD TKAPKRQEME SGITTPPKMR RVAETDYEME
     TQRISSSQQH PHLRKVSVSE SNVLLDEEVL TDPKIQALLL TVLATLVKYT TDEFDQRILY
     EYLAEASVVF PKVFPVVHNL LDSKINTLLS LCQDPNLLNP IHGIVQSVVY HEESPPQYQT
     SYLQSFGFNG LWRFAGPFSK QTQIPDYAEL IVKFLDALID TYLPGIDEET SEESLLTPTS
     PYPPALQSQL SITANLNLSN SMTSLATSQH SPGIDKENVE LSPTTGHCNS GRTRHGSASQ
     VQKQRSAGSF KRNSIKKIV
//
